Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection

Phase 3 Completed 492 enrolled University of Mississippi Medical Center National Center for Complementary and Integrative Health (NCCIH) · collab

RandomizedParallel-groupQuadruple-blindSupportive care

Summary

This randomized, double blind, placebo controlled study aims to establish the impact of the oral supplement, Immulina TM, on enhancing host resilience to the effects of viral influenza infection in humans.

Timeline

Start: 2022-07-01
Primary completion: 2025-12-08
Completion: 2025-12-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	spirulina	Unknown	200 mg	Oral
Subject	spirulina	Unknown	400 mg	Oral
Subject	spirulina	Unknown	800 mg	Oral

Indications

No indication recorded.